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ABSTRACT 
This is an overview of the development of microemulsion systems containing amphotericin B for ophthalmic use. The amphotericin 
B (AmB) is used to treat a fungal infection of eye and bioavailability of the AmB is the challenge for the research scientist. The poor 
bioavailability of AmB is due mainly to the corneal barrier, which eventually leads to a precorneal loss and subsequent decrease in 
the absorption of this drug into the intraocular tissues. Also, AmB has limited permeation across the intact corneal epithelium, which 
along with the toxicity associated with this molecule, epitomizes a major drawback to its clinical use. Therefore, new effective and 
safe drug vehicles for ocular delivery of AmB are urgently required. Recently, microemulsions (MEs) have been used in ophthalmic 
drug delivery system owing to their thermodynamic stability, transparent appearance, and favorable viscosity. Information and 
proper understanding of the physical chemistry and process of formation of AmB-containing MEs would provide reliable 
information on the best conditions for the use of these systems as eye drops. The aim of this research was thus to review the main 
studies on the use of MEs as delivery systems for AmB in topical eye treatment. 
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INTRODUCTION 
Ocular diseases are mainly treated by topically applied 
drug administered by eye drops. These conventional 
dosage forms correspond to 90% of the available 
ophthalmic formulations, however, the rapid pre-corneal 
loss associated with nasolacrimal drainage and the 
presence of tears make this fact one of the major 
problems associated with the absorption of drugs in the 
eye
1, 2
. Nanotechnology is emerging as a promising 
alternative for developing a large range of drug delivery 
systems for the treatment of diseases via the ocular 
route
3
. These systems, called colloidal mostly can 
substantially aid in current therapy which employs 
periocular route as the route of administration
3, 4
. 
The treatment of conditions such as keratitis caused by 
fungal infectious agents leads to serious suppurative 
infections, eventually leading to ulcerations in the 
involved tissues and have a generally grim prognosis, 
and the treatment depends on the rapid and efficient 
diagnosis. However, in addition to the challenges posed 
by the anatomical nature of the eye, the treatment of 
these pathologies still generates uncertainty about the 
clinical protocols to be established
5
. 
Amphotericin B (AmB) is a polyene antifungal agent, 
broad - spectrum of action, which is widely used in the 
treatment of systemic and ocular fungal infections
6, 
7
. The drug consists of an orange-yellow powder which 
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has two important physicochemical properties: an 
amphiphilic behavior due to the nonpolar and polar 
groups of the lactone ring and an amphoteric behavior 
due to the presence of ionizable carboxyl and amino 
groups. Due to these characteristics, AmB molecule is 
poorly soluble in aqueous solvents and many organic 
solvents, and its solubility in water at physiological pH 
(pH 6-7) of less than 1 mg / ml
8
. 
The current formulation of AmB (Fungizone
®
) contains 
sodium deoxycholate (surfactant needed to promote 
micellization of AmB) causes during instillation, severe 
pain (irritability) which lead to non -adherence to the 
treatment by the patient and consequently, worsening of 
symptoms
9
. This toxicity associated with the topical 
ocular administration, may develop through blepharitis, 
keratitis, and iritis that according to the literature, relates 
to this surfactant and can be significantly reduced 
when the lipid formulations are used as vehicles for the 
incorporation of the drug without the use of this 
substance
10, 11
. 
The aim of this review article is, therefore, to address 
the main aspects of the development and preparation of 
microemulsions (MEs) as delivery systems for AmB 
through via topical ocular administration
12-14
. 
Development and preparation of microemulsions for 
use in the eye 
Although discovered since 1928, the potential of EMs as 
drug delivery systems for the ophthalmic route has only 
been explored in the past twenty years
15
. Moreover, as 
mentioned earlier, the eye is not an easily accessible 
organ mainly due to the constant presence of 
nasolacrimal drainage and corneal barrier
16
. In this 
context, the MEs are presented as an interesting 
therapeutic alternative for the ophthalmic route. In fact, 
MEs have a great capacity for delayed action based on 
the adsorption of nano-droplets, therefore, will not be 
deleted by the nasolacrimal drainage. In such systems, 
the cornea will act as a reservoir molecules increasing 
its bioavailability
15
. 
The MEs also correspond to a promising alternative to 
reduce the adverse effects caused by AmB
17, 18
. These 
systems are composed of two immiscible liquids, 
transparent (translucent isotropic) and 
thermodynamically stable because they are stabilized by 
an interfacial film of surfactant localized at the oil / 
water interface
19
. ME yet have additional advantages 
such as ease of production and sterilization, increased 
the ability to incorporate both hydrophilic drugs such as 
lipophilic, small droplets of internal phase viscosity 
suitable for the release of drugs in the eye, high surface 
area, ultra-low interfacial tension , high stability and 
low
15, 20-22
. 
To develop and prepare these systems, many factors 
must be considered according to the desired type of ME, 
which in turn is determined during the development of 
pseudo-ternary phase diagrams (DFPT).The factors that 
lead to thermodynamic stability, which influence the 
release of the formulation of pharmaceuticals
23
, the 
requirements concerning the necessary components and 
potential uses and limitations of a microemulsion system 
by the ocular route must, therefore, be taken into 
consideration
24-26
. 
As regards the necessary ingredients,
15
 described the use 
of various substances considered biocompatible for use 
by this route of administration, emphasizing its main 
characteristics and purposes, as its implementation and 
use, specifically the oil and aqueous phases
15
. In this 
article, there is a description of the main surfactants that 
can be part of the formulations, as well as its 
restrictions. In fact, on an ME, the surfactants serve not 
only to stabilize the system thermodynamically, but also 
to facilitate the incorporation of the proposed 
drug. From a physiological point of view, the surfactant 
may contribute to the drug absorption in the eye by 
ensuring cornea, with that, increased homogenization of 
the system with the cell layers and better contact with 
the epithelium, causing greater absorption thereof into 
tissues later. On the other hand, should be balanced for 
high concentrations of surfactants are not used, thus 
avoiding the occurrence of local toxicity
15
. 
From a technological point of view, the MEs can be 
formulated in three types: oil in water (O / W), water in 
oil (W / O) or bicontínuos systems
27
. To form these 
systems, in particular, two aspects should be taken into 
account in the choice of components: the oil and the 
quantity in the formulation and the hydrophilic-
lipophilic balance (HLB) of surfactants involved
21, 28
. 
For the development of a simple microemulsion system, 
the preparation and study of DFPT are sorely 
needed. Usually, a DFPT is constructed to determine the 
composition of the oil phase, water, and surfactants that 
will be part of ME. Water, oil and a ratio of two 
surfactants are represented at each corner of the 
diagram, these being corresponding to 100% of the 
particular components. The proportions of each 
component are therefore described using these 
diagrams , and they must be combined to form clear and 
transparent systems, consisting of an important feature 
for the use of such formulations through the ocular 
use
24
. 
The ME of the formation process requires, first, the 
determination of the ME region of DFPT, in which can 
be observed by viewing various mixtures of surfactants 
and the oil and water phases used
15
. 
The first process emphasizes the ME's ability to form 
spontaneously. They can be prepared in a single step by 
simple mixing of the components in their ideal 
proportions. The order of addition of components is not 
regarded as a crucial factor in the formation process, but 
can influence the time necessary to achieve 
equilibrium
15
. 
In the process with power supply, the ME is not formed 
spontaneously. In this process, a decrease in the amount 
of surfactants, and sometimes necessary, results in the 
necessity of using high-pressure homogenizers , in order 
to obtain droplets of a desirable size, which constitute 
the internal phase and to have a higher speed the process 
of formation
15
. 
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The development of new systems for ocular use, the 
formulator must consider multiple perspectives. In 
addition to the physiological barriers imposed by the eye 
and shortcomings of conventional dosage forms to 
promote adequate absorption, many drugs will not have 
favorable characteristics for use by this route and due to 
their clinical importance in the treatment of various 
diseases; they continue to be administered by adverse 
patient conditions. Thus, after the choice of likely 
microemulsion systems from DFPT, it is necessary to 
characterize these systems with and without the drug in 
order to obtain a formulation encompassing all ocular 
administration route requirements and favoring clinical 
and necessary technological
29
. One final aspect to be 
considered in the development of EMs for the ocular 
route is its safety regarding eye irritation and possible 
pre-corneal retention. Alany et al 
30
, studied this point 
and the assumption that the phase transition of an ME, 
induced by the presence of tears, turning into liquid 
crystals could prolong the pre-corneal retention of 
molecules. They came to the conclusion that this 
phenomenon can effectively occur, but that the MEs 
have nevertheless a great protective effect compared 
with aqueous solutions and can, therefore, be used as 
carriers in the principles of active hydrophilic high 
irritant power
30
. 
INCORPORATION OF AMB 
Many problems related to the administration of AmB to 
give local effect in the eye. Intravenous administration is 
often related to the control of fungal infections in 
posterior segment (endophthalmitis)
31
, but severe renal 
toxicity associated with systemic effect and small 
intraocular penetration limits its use in higher 
concentrations
32-34
. The conjunctival administration of 
AmB causes severe necrosis at the site of application, 
thus its use is not recommended
10
. On the other hand, 
the intravitreal administration of AmB is associated 
with the possible toxicity of the retina and its possible 
displacement if its application is not held exactly in the 
center of the vitreous humor
32
. However, intracameral 
administration of AmB has been proven effective in the 
treatment of lesions with subsequent appearance of 
minimal toxicity reactions however the efficiency of this 
mode of administration is hampered by a lack of further 
trials. All of these forms, commonly performed in the 
clinic, bring inconveniences to the patients who need 
them and not always results are shown satisfactory
35-38
. 
The use of carrier lipid to incorporate AmB has been 
described in recent years by several groups, but none of 
them assigned the job of ME to ocular
6, 17, 18
.The 
physicochemical characteristics of EMs, with the aim of 
carrying AmB, can be adapted to the point of promoting 
its use through this route and consist in future in a new 
system able to be administered by applying eyedrops
29
. 
Despite the intrinsic characteristics of AmB, 
incorporation of this drug can be difficult. Despite its 
low solubility in water and in oil (amphoteric nature) 
under physiological pH conditions, the use of alkaline 
solutions has been shown to promote solubilization 
of the drug and can easily be used
17-19, 29
. 
The AmB content of microemulsion systems can be 
determined by using analytical methods such as high-
performance liquid chromatography and by reverse 
phase spectrophotometry. The results determined by 
such techniques show that the AmB can be easily 
detected when incorporated into MEs, being located 
at the oil-water interface , or even within the droplet oil 
which forms the internal phase, thus presenting an 
encapsulation rate ( incorporation) around 100%
18, 29, 39
. 
DETERMINING THE PHYSICOCHEMICAL 
CHARACTERISTICS 
Ideal macroscopically 
Macroscopic characteristics allow to emphasize that 
these systems have the requirements of a true ME and 
the presence of AmB is or is not able to alter the 
intrinsic features necessary for an ophthalmic system 
without the drug presented by the system. The clarity, 
homogeneity, absence of particulate matter, creaming or 
phase separation, in addition to transparency and 
thermodynamic stability correspond to essential factors 
of the MEs that should remain unchanged even after the 
addition of the drug
40
. 
The classification proposed by Winsor in 1948 to 
disperse systems, requires single phase, the Winsor IV 
type is preferable as drug delivery 
systems. Transparency, clarity, and homogeneity of the 
phases are features present in EMs and extremely 
important for the administration through the ocular
41
. 
pH range 
The AmB has maximum therapeutic activity in the pH 
range between 6.0 and 7.5
42
. In addition, this track is 
very important to promote the necessary comfort to the 
patient when the formulation is administered in the 
eye. If the pH of the composition is outside this range, a 
possible irritation may arise, with possible damages to 
the tissues, inducing a greater tearing
20, 43
,greater 
elimination of AmB compromising its bioavailability 
and its efficacy in affected tissues
44
. The use of tampons 
as the aqueous phase consists of a fact very important to 
ensure that there will be variations in the required pH 
range, keeping, thus, the comfort to the patient upon 
administration and maximum activity of AmB in MEs 
proposals
15
. 
Refractive index and transmittance percentage 
Transparency is a very important factor to be noted, as 
should the patient avoid the occurrence of blurred vision 
and discomfort after administration of the 
microemulsion system in the eye. This can be easily 
observed in EMs, due to the proximity of their values to 
the refractive index presented by the tears and the 
cornea, thus consisting of one of its main advantages for 
use by ocular route
21, 45
. The transmittance percentage 
above 99% corroborates this parameter together and 
prove that the system really has obtained transparency
46
. 
Recently it was demonstrated that the presence of AmB 
incorporated in an ME is able to partially reduce this 
transparency. However, such change does not influence 
the initial system stability and homogeneous and 
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transparent characteristic described in Winsor IV 
classification is thus maintained
29
. 
Conductivity 
MEs type O / A has been proposed as aqueous vehicles 
for the release of numerous drug 
molecules. Conductivity is an important parameter in 
characterizing the MEs, because it is able to determine 
the type of ME formed from the combination of its 
components. This test claims to have an ME aqueous or 
oily external phase based on the same capacity to 
conduct electrical current
47
. 
The use of BD aqueous outer phase is more appropriate 
for administration by the ocular route, because during its 
application, this system is able to mix and distribute 
tears, maintaining the uniformity of the droplets with the 
same and ensuring the better release of AmB in the 
cornea
48
. 
Droplet size and polydispersity index 
The determination of droplet size and its distribution 
corresponds to one of the most important parameters to 
evaluate the stability of microemulsion systems and the 
influence of the incorporation of poorly soluble drugs 
which could cause instability of the system
49
. The small 
size of the order of 50 nanometers, characterized ME 
and it is due to the interaction between the molecules of 
the cosurfactant to the surfactant film on the internal 
phase, thus decreasing the radius of curvature of the 
microdroplets, providing training of transparent 
systems
24, 29
. 
Some studies reported in the literature show that the 
incorporation of AmB the droplet size increases initially 
originated with the ME without the drug. This is 
probably the intrinsic physicochemical properties of the 
molecule (anfotericidade and amphiphilicity) who take 
the drug to be located within the droplet or even in their 
interfacial region. However, this fact cannot change the 
system stability and isotropic properties are therefore 
retained
19, 29
. 
Surface tension 
The vast majority of authors who develop 
microemulsion systems states that the application of a 
negative free energy is required for the spontaneous 
formation is optimized. This achievement is 
accompanied by dramatic reductions in surface tension 
present between the aqueous and oil phase. For this to 
be provided, high surfactant concentrations should be 
used by increasing thereby the risk of toxicity
48, 50
. 
In some cases, it is necessary to decrease the amount of 
surfactants and increase the proportion of the aqueous 
phase to obtain a given microemulsion system. Thus, 
probably surface tension show variations and this will 
require the formulator the use of other methodologies 
system training, as well as the use of other devices for 
the incorporation of drugs which require higher 
concentrations of these substances,  exert their 
activities
15
. 
The surface tension should therefore not be influenced 
by the addition of the drug, it being essential for the 
maintenance of the thermodynamic stability of the ME 
before and after incorporation and must remain the best 
ratio between components
29
. 
Zeta potential 
The human corneal surface is negatively charged, so the 
use of internal phase microemulsion systems which 
present positive charge can directly influence the 
absorption of AmB by topically. Studies have shown 
that positively charged PMs are suitable for use by this 
route. The electrostatic attraction between positively 
charged PMs with the negative surface of the cornea 
generates a bioadhesion due to the connection between 
the opposite charges, causing an increase in drug 
absorption. Therefore, the development of PMs with 
zeta potential suitable for topical administration would 
act by increasing the AmB time of contact with the 
corneal surface favoring their absorption and thereby 
increasing the biodisponililidade the posterior tissues of 
the eye
51, 52
. 
Isotonic 
The use of isotonizing agents should be contained in the 
aqueous phase as well as the use of buffering 
agents
53
. The need to formulate isotonic systems for the 
eyes is also linked to comfort the pharmaceutical form 
will give the patient when it is 
administered. However, one should be very careful, 
because the use of salinizantes agents may decrease the 
temperature of phase inversion of surfactants causing a 
change in the external phase system promoting a 
decrease of stability in concomitant use with ionic 
surfactants
15
. 
Viscosity and rheology 
Ocular therapy with AmB - containing systems could be 
significantly improved if the pre-corneal contact time is 
increased. The increase in contact time can provide 
increased absorption of drugs through the cornea 
and to reduce the systemic adverse effects displayed by 
conventional dosage forms
54
. The expected viscosity 
values must be present above those that are observed for 
conventional ophthalmic solutions (approximately 20 
MPa) in order to provide a higher AMB retention time 
of the corneal surface and allow a greater penetration 
of the drug into the eye
21
. 
The determination of viscosity and rheological behavior 
in EMs is required to physically characterize and control 
their stability
17
. These parameters are important when 
the molecule is administered by ocular route.0 The 
presence of AmB incorporated into the system should 
not cause changes in rheological behavior as occasional 
changes would provide problems with respect to the 
ocular administration and stability of the system 
itself. There is also the system, depending on the 
purpose of the formulator can present several 
rheological behaviors, the most important being the 
Newtonian. This behavior ensures that the formulations 
will not change in viscosity with the tearing and the 
action of the eye blink. 
Chirlekar et al                                                   Journal of Drug Delivery & Therapeutics. 2016; 6(6):54-59                   58 
© 2011-16, JDDT. All Rights Reserved                                            ISSN: 2250-1177                                                    CODEN (USA): JDDTAO 
The viscosity values should allow further that the 
systems can be sterilized by filtration, a factor essential 
in the development of pharmaceutical forms for ocular 
administration, as it ensures the absence of any 
microbiological contamination
21
. 
CONCLUSION 
The development of new systems for the carrier AmB to 
improve its bioavailability and reduce its toxicity as well 
as the drawbacks presented with the administration of 
conventional forms of a pharmaceutical formulation 
(Fungizone
®
), if necessary. In the near future, emphasis 
should be given for the treatment of ocular disorders 
using a non-invasive molecules delivery system and 
capable of reaching all segments of the eye. In this 
context, MEs appear as a promising system since they 
possess physicochemical properties that allow its use 
over the ocular route. MEs also consist of suitable 
systems incorporating other poorly soluble drugs, 
becoming a new alternative for the treatment of 
superficial fungal infections and other internal disorders 
that affect the eye. The use of MEs containing AmB 
(AmB ME) should be able to maintain efficacy, improve 
bioavailability and reduce the toxicity observed for the 
AmB when used via the intravenous and ocular routes in 
control of systemic fungal infections and ocular. 
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